FoundationFocus CDx BRCA HRD

Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System

FDA Premarket Approval P160018 S001

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the foundationfocus™ cdx brca loh. The device is an assay that uses next-generation sequencing (ngs) for qualitative detection of brca1 and brca2 sequence alterations and genomic loss of heterozygosity (loh) from formalin-fixed, paraffin-embedded (ffpe) ovarian tumor tissue. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious tumor brca variants (tbrca-positive), who may be eligible for treatment with rubraca (rucaparib). Positive homologous recombination deficiency (hrd) status (defined as tbrca-positive or loh high) in ovarian cancer patients is associated with improved progression-free survival (pfs) from rubraca (rucaparib) maintenance therapy. See the rubraca product label for information about guiding therapy in specific clinical circumstances. This test is to be performed at foundation medicine, inc. , a single laboratory site, located at 150 second street, cambridge, massachusetts.

DeviceFoundationFocus CDx BRCA HRD
Classification NameNext Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
Generic NameNext Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
ApplicantFOUNDATION MEDICINE, INC
Date Received2017-09-28
Decision Date2018-04-06
Notice Date2018-04-23
PMAP160018
SupplementS001
Product CodePQP
Docket Number18M-1446
Advisory CommitteePathology
Supplement TypePanel Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address FOUNDATION MEDICINE, INC 150 Second Street, 1st Floor cambridge, MA 02141
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P160018Original Filing
S001 2017-09-28 Panel Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.